A Paoli medical device company is cutting the fear out of critical surgeries to remove cancer.

Dune Medical Devices’ MarginProbe detects the unique electromagnetic properties of cancer cells, and alerts surgeons to their presence while still in the operating room, according to a report in The Wall Street Journal by Lucette Lagnado.

The result: Dune Medical’s innovation can help cut out repeat surgeries to get lingering cancer cells, which are needed 20-30 percent of the time and can cost $9,000-$16,000 or more.

“You need to be able to say to the patient, ‘One outpatient surgery and you are done,’” said Freya Schnabel, Perlmutter Cancer Center Director of Breast Surgery.

One trial of almost 600 breast cancer patients cut second surgeries by 26 percent, and other studies by Dune Medical show it can reduce re-surgeries by 50 percent.

“It sounded too good to be true,” said Hall-Perrine Cancer Center Medical Director Vincent Reid. “The more I used it, the more I trusted the technology.”

Read more about Dune Medical’s MarginProbe in The Wall Street Journal here.